WO2011121598A1 - Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof - Google Patents

Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof Download PDF

Info

Publication number
WO2011121598A1
WO2011121598A1 PCT/IN2010/000312 IN2010000312W WO2011121598A1 WO 2011121598 A1 WO2011121598 A1 WO 2011121598A1 IN 2010000312 W IN2010000312 W IN 2010000312W WO 2011121598 A1 WO2011121598 A1 WO 2011121598A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
isopropyl
oxo
methyl
fluorophenyl
Prior art date
Application number
PCT/IN2010/000312
Other languages
French (fr)
Inventor
Sivakumar Ramasamy
Thangarasu Ponnusamy
Anegondi Sreenivasa Prasad
Srinivas Pullela Venkata
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of WO2011121598A1 publication Critical patent/WO2011121598A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Definitions

  • the invention describes an elegant process for the preparation of Rosuvastatin Intermediate in the solid state and isolation of substantially pure crystalline form thereof.
  • Rosuvastatin calcium which is chemically known as Calcium (+)-7-[(4-(4-fiuorophenyl)-6- isopropyl-2-(N-acetyl-N-methyl amino) pyrimidin-5-yl)] - (3R,5S)-dihydroxy-6-(E)- Heptenoate, developed by Shinogi is used in the treatment of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.Rosuvastatin Calcium has the following Chemical Formula.
  • Rosuvastatin Calcium A number of relevant processes for the preparation of Rosuvastatin Calcium, Intermediates and thereof are disclosed .
  • One of the Important intermediates in the preparation of Rosuvastatin Calcium is Compound of formula 2, disclosed in U.S. Patent No.RE37,314E which is chemically named as Methyl-(+)-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N- methanesulfonylamino) pyrymidine-5-yl) - (3R) -Hydroxy-5-Oxo-6 - (E)-Heptonoate.
  • the present invention relates to a crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6- Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate which provides at least one of: (i) FTIR spectra of crystalline form of Compound-2 with peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1 157, 960, 903, 851, 808, 778, 565, 523, 490 cm “1 , (ii) DSC thermogram of crystalline form with endothermic peak at 105.70°C; and/or (iii) an X-ray powder diffraction (XRPD) pattern with 5.917, 7.607,8.193, 8.88, 9.815, 10.11, 1 1.633, 12.
  • the present invention is in relation to a crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6- Heptonoate which provides at least one of:
  • the crystalline form of Methyl-7-(4-(4- Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5- Oxo-6-Heptonoate is in isolated form.
  • the crystalline form of Methyl-7-(4- (4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy- 5-Oxo-6-Heptonoate is in pure form.
  • the crystalline form of Methyl-7-(4- (4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy- 5-Oxo-6-Heptonoate is in crystalline form.
  • the present invention is also in relation to a process for preparing crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5- yl)-Hydroxy-5-Oxo-6-Heptonoate , comprising steps of:
  • the hydrogen halides are selected from HC1 and HF.
  • the solvent is selected from C I- C4 aliphatic alcohols.
  • C I - C4 aliphatic alcohol is selected from a group comprising methanol, ethanol and isopropyl alcohol.
  • the main objective of the invention is to provide a method for the preparation of the Rosuvastatin Intermediate 7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl- amino)- pyrimidin-5-yI]-3(R) - hydroxy-5-oxo-hept-6-enoic acid methyl ester (Compound- 2) in solid state with good yield, high purity and ease of operations.
  • the intermediate is further characterized by well established techniques like XRD, DSC and FTIR.
  • the present invention provides a method for the preparation of Rosuvastatin intermediate (Compound- 2) using simple process in a substantially pure crystalline form. It involves the deprotection of tert-Butyl dimethyl silyl group (TBDMS) of 3(R)-(tert-Butyl-dimethyl-silanyloxy)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2- (methanesulfonyl -methyl-amino)-pyrimidin-5-yl]-5-oxo-hept-6-enoic acid methyl ester (Compound- 1) using hydrogen halides (HC1, HF) in appropriate concentrations in an aliphatic alcohol as a solvent preferably methanol. Without any additional purification the product is directly isolated from the reaction mixture.
  • TDMS tert-Butyl dimethyl silyl group
  • the present invention provides a crystalline form of Compound- 2 having the X-ray diffraction pattern with peaks at 5.917, 7.607, 8.193, 8.88, 9.815, 10.11, 1 1.633, 12.202, 13.729, 14.725, 14.81, 15.193, 15.549, 16.2, 16.411, 16.976, 18.159, 19.024, 19.513, 19.74, 20.311, 20.875, 21.345, 21.943, 22.651, 23.563, 24.082, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ⁇ 0.2 degrees two theta values.
  • the present invention provides FTIR spectra of crystalline form of Compound-2 with peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1 157, 960, 903, 851, 808, 778, 565, 523, 490 cm “1 .
  • the present invention provides DSC thermogram of crystalline form of Compound- 2 with endothermic peak at 105.70°C.
  • the present invention provides a method for the preparation of Compound-2 comprising the steps of:
  • Solvents can be selected from a group consisting of CI- C4 aliphatic alcohols like methanol, ethanol and IPA, most preferably methanol. Solvent is in an amount of 5-20 vol, most preferably 10 vol relative to Compound -1.
  • reactions are carried out using hydrogen halides like HF or HC1 in suitable concentrations in above mentioned solvent.
  • Hydrogen halide concentrations in case of HC1 may be selected between 1.0 - 10.0 % as an aqueous solution, preferably between 1.0 - 3.0 % and in case of HF may be selected between 5.0 - 20.0 % as an aqueous solution, preferably between 5.0 -10.0 %.
  • reactions stirring time is selected between 10 - 50 hrs, preferably 25-30 hrs which may vary depending on the reaction conditions.
  • the resulting crystalline solids from the above mentioned aspects is recovered by conventional techniques like filtration.
  • the crystals are then dried. Drying may be carried out at a temperature less than 60°C under vacuum.
  • the invention encompasses a crystalline form of compound - 2 characterized by powder X-Ray Diffraction pattern having Prominent peaks at 9.815, 16.2, 18.159, 19.513, 19.74, 20.875, 21.345, 21.943, 22.651, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ⁇ 0.2 degrees two theta values.
  • the crystalline form may be further characterized by X-Ray powder diffraction peaks at about 5.917, 7.607,8.193, 8.88, 9.815, 10.1 1, 1 1.633, 12.202, 13.729, 14.725, 14.81, 15.193, 15.549, 16.2, 16.41 1 , 16.976, 18.159, 19.024, 19.513, 19.74, 20.31 1, 20.875, 21.345, 21.943, 22.651, 23.563, 24.082, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ⁇ 0.2 degrees two theta values.
  • Crystalline intermediate of the present invention shows main FTIR peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1 157, 960, 903, 851, 808, 778, 565, 523, 490 cm- 1 .
  • DSC thermogram for crystalline Rosuvastatin intermediate of present invention shows an endothermic peak at about 105.70 °C.
  • the crystalline form of Compound-2 may be converted into Rosuvastatin and its pharmaceutically acceptable salts by conventional methods.
  • Rosuvastatin intermediate of the present invention (Compound - 2) is characterized by X- Ray powder Diffraction (XRD), DSC analysis, and FTIR spectroscopy.
  • XRD XRD Diffractograms were collected on Bruker AXS D-8 advance X- Ray powder diffract meter, Scintillation detector. Scanning Parameters : ScanType - Locked Coupled, Scan Mode -Continuous, Range (2 theta) - 3.0°- 60.0°, Rate - 3.6 min
  • FTIR Spectroscopy FTIR Spectrum was recorded on Perkin-Elmer spectrum- 1 spectrometer, Diffuse Reflectance Technique. The sample was finely ground with Potassium Bromide, and the spectrum was recorded using Potassium Bromide background in a Diffused reflectance accessory.
  • Example 3 Preparation of Compound- 2 using 3.0% HC1 /Methanol A mixture of 3.0%HC1 (8.0ml), Compound -l(3.0g) and methanol (20ml) was stirred at ambient temperature for about 15 - 20 hrs. The separated solid was filtered, washed with water and dried under vacuum for 10 hrs yielding compound- 2 ( 1.8g) as a pale yellow crystalline solid .

Abstract

The present invention is related to a crystalline form of 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl- amino)-pyrimidin-5-yl]-(3R)-hydroxy-5-oxo-hept-6-enoic acid methyl ester which is a Rosuvastatin intermediate. The invention also provides a method for the preparation and isolation in the form of the Rosuvastatin intermediate.

Description

"CRYSTALLINE 7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- (METHANESULFONYL-METHYL- AMINO)- PYRIMIDIN-5-YL]-3(R) - HYDROXY-5-OXO-HEPT-6-ENOIC ACID METHYL ESTER AND PROCESS
THEREOF.
FIELD OF INVENTION
The invention describes an elegant process for the preparation of Rosuvastatin Intermediate in the solid state and isolation of substantially pure crystalline form thereof. BACK GROUND OF INVENTION
Rosuvastatin calcium which is chemically known as Calcium (+)-7-[(4-(4-fiuorophenyl)-6- isopropyl-2-(N-acetyl-N-methyl amino) pyrimidin-5-yl)] - (3R,5S)-dihydroxy-6-(E)- Heptenoate, developed by Shinogi is used in the treatment of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.Rosuvastatin Calcium has the following Chemical Formula.
Figure imgf000002_0001
Rosuvastatin Calcium
A number of relevant processes for the preparation of Rosuvastatin Calcium, Intermediates and thereof are disclosed .One of the Important intermediates in the preparation of Rosuvastatin Calcium is Compound of formula 2, disclosed in U.S. Patent No.RE37,314E which is chemically named as Methyl-(+)-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N- methanesulfonylamino) pyrymidine-5-yl) - (3R) -Hydroxy-5-Oxo-6 - (E)-Heptonoate.
Figure imgf000003_0001
Figure imgf000004_0001
Rosuvastatin Calcium
US RE 37314E, describes the preparation of the Compound of formula 2 and WO03/097614 teaches isolation as syrup by column chromatography, WO 03/087112 describes the preparation of tert-butyl ester of the same compound and isolated in the pure form by Column chromatography.
Nevertheless there remains a need of processes for the preparation of Rosuvastatin which is cost effective with simple purification steps. Further the process is suitable for industrial scale preparation.
STATEMENT OF INVENTION
The present invention relates to a crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6- Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate which provides at least one of: (i) FTIR spectra of crystalline form of Compound-2 with peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1 157, 960, 903, 851, 808, 778, 565, 523, 490 cm"1, (ii) DSC thermogram of crystalline form with endothermic peak at 105.70°C; and/or (iii) an X-ray powder diffraction (XRPD) pattern with 5.917, 7.607,8.193, 8.88, 9.815, 10.11, 1 1.633, 12.202, 13.729, 14.725, 14.81, 15.193, 15.549, 16.2, 16.41 1, 16.976, 18.159, 19.024, 19.513, 19.74, 20.31 1, 20.875, 21.345, 21.943, 22.651, 23.563, 24.082, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ± 0.2 degrees two theta values and a process for preparing crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5- yl)-Hydroxy-5-Oxo-6-Heptonoate , comprising steps of: a. reacting 3(R)-(tert-Butyl- dimethyl-silanyloxy)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2-(methanesulfonyl-methyl- amino)-pyrimidin-5-yl]-5-oxo-hept-6-enoic acid methyl ester with aqueous hydrogen halides of appropriate concentrations in an aliphatic alcohol as a solvent and isolating crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate by filtration.
DETAILED DESCRIPTION OF INVENTION
The present invention is in relation to a crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6- Heptonoate which provides at least one of:
(i) FTIR spectra of crystalline form of Compound-2 with peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1157, 960, 903, 851, 808, 778, 565, 523, 490 cm'1,
(ii) DSC thermogram of crystalline form with endothermic peak at 105.70°C; and/or (iii) an X-ray powder diffraction (XRPD) pattern with 5.917, 7.607,8.193, 8.88, 9.815, 10.11, 1 1.633, 12.202, 13.729, 14.725, 14.81, 15.193, 15.549, 16.2, 16.411, 16.976, 18.159, 19.024, 19.513, 19.74, 20.311, 20.875, 21.345, 21.943, 22.651, 23.563, 24.082, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ± 0.2 degrees two theta values.
In another embodiment of the present invention, the crystalline form of Methyl-7-(4-(4- Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5- Oxo-6-Heptonoate is in isolated form.
In still another embodiment of the present invention, the crystalline form of Methyl-7-(4- (4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy- 5-Oxo-6-Heptonoate is in pure form. In still another embodiment of the present invention, the crystalline form of Methyl-7-(4- (4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy- 5-Oxo-6-Heptonoate is in crystalline form.
The present invention is also in relation to a process for preparing crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5- yl)-Hydroxy-5-Oxo-6-Heptonoate , comprising steps of:
a. reacting 3(R)-(tert-Butyl-dimethyl-silanyloxy)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2- (methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-5-oxo-hept-6-enoic acid methyl ester with aqueous hydrogen halides of appropriate concentrations in an aliphatic alcohol as a solvent; and
b. isolating crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate by filtration.
In still another embodiment of the present invention, the hydrogen halides are selected from HC1 and HF.
In still another embodiment of the present invention, the solvent is selected from C I- C4 aliphatic alcohols.
In yet another embodiment of the present invention, C I - C4 aliphatic alcohol is selected from a group comprising methanol, ethanol and isopropyl alcohol.
The main objective of the invention is to provide a method for the preparation of the Rosuvastatin Intermediate 7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl- amino)- pyrimidin-5-yI]-3(R) - hydroxy-5-oxo-hept-6-enoic acid methyl ester (Compound- 2) in solid state with good yield, high purity and ease of operations. The intermediate is further characterized by well established techniques like XRD, DSC and FTIR.
Figure imgf000007_0001
1 2
In one embodiment the present invention provides a method for the preparation of Rosuvastatin intermediate (Compound- 2) using simple process in a substantially pure crystalline form. It involves the deprotection of tert-Butyl dimethyl silyl group (TBDMS) of 3(R)-(tert-Butyl-dimethyl-silanyloxy)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2- (methanesulfonyl -methyl-amino)-pyrimidin-5-yl]-5-oxo-hept-6-enoic acid methyl ester (Compound- 1) using hydrogen halides (HC1, HF) in appropriate concentrations in an aliphatic alcohol as a solvent preferably methanol. Without any additional purification the product is directly isolated from the reaction mixture.
In another embodiment, the present invention provides a crystalline form of Compound- 2 having the X-ray diffraction pattern with peaks at 5.917, 7.607, 8.193, 8.88, 9.815, 10.11, 1 1.633, 12.202, 13.729, 14.725, 14.81, 15.193, 15.549, 16.2, 16.411, 16.976, 18.159, 19.024, 19.513, 19.74, 20.311, 20.875, 21.345, 21.943, 22.651, 23.563, 24.082, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ± 0.2 degrees two theta values. In another embodiment the present invention provides FTIR spectra of crystalline form of Compound-2 with peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1 157, 960, 903, 851, 808, 778, 565, 523, 490 cm"1.
In another embodiment the present invention provides DSC thermogram of crystalline form of Compound- 2 with endothermic peak at 105.70°C.
The present invention provides a method for the preparation of Compound-2 comprising the steps of:
a) Reacting compound- 1 with aq hydrogen halides (HF, HC1) of appropriate concentrations in an aliphatic alcohol as a solvent.
b) Isolating the Solid Compound-2 by filtration
In a particular preferred embodiment Solvents can be selected from a group consisting of CI- C4 aliphatic alcohols like methanol, ethanol and IPA, most preferably methanol. Solvent is in an amount of 5-20 vol, most preferably 10 vol relative to Compound -1.
In another embodiment, reactions are carried out using hydrogen halides like HF or HC1 in suitable concentrations in above mentioned solvent.
Hydrogen halide concentrations in case of HC1 may be selected between 1.0 - 10.0 % as an aqueous solution, preferably between 1.0 - 3.0 % and in case of HF may be selected between 5.0 - 20.0 % as an aqueous solution, preferably between 5.0 -10.0 %.
In another aspect of invention, reactions stirring time is selected between 10 - 50 hrs, preferably 25-30 hrs which may vary depending on the reaction conditions. The resulting crystalline solids from the above mentioned aspects is recovered by conventional techniques like filtration. The crystals are then dried. Drying may be carried out at a temperature less than 60°C under vacuum.
The invention encompasses a crystalline form of compound - 2 characterized by powder X-Ray Diffraction pattern having Prominent peaks at 9.815, 16.2, 18.159, 19.513, 19.74, 20.875, 21.345, 21.943, 22.651, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ± 0.2 degrees two theta values. The crystalline form may be further characterized by X-Ray powder diffraction peaks at about 5.917, 7.607,8.193, 8.88, 9.815, 10.1 1, 1 1.633, 12.202, 13.729, 14.725, 14.81, 15.193, 15.549, 16.2, 16.41 1 , 16.976, 18.159, 19.024, 19.513, 19.74, 20.31 1, 20.875, 21.345, 21.943, 22.651, 23.563, 24.082, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ± 0.2 degrees two theta values.
Crystalline intermediate of the present invention shows main FTIR peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1 157, 960, 903, 851, 808, 778, 565, 523, 490 cm-1.
The most intense peaks appear at 3515, 2969, 1747, 1662, 1541, 1508, 1379, 1326, 1229, 1 157, 960, 851 , 778, 565, 523 cm"1
DSC thermogram for crystalline Rosuvastatin intermediate of present invention shows an endothermic peak at about 105.70 °C.
In yet another embodiment of the present invention the crystalline form of Compound-2 may be converted into Rosuvastatin and its pharmaceutically acceptable salts by conventional methods.
In the present invention starting material (Compound- 1) for the preparation of the said intermediate was prepared according to the known processes in the prior art.
The invention is further illustrated by the following examples, which should not be construed to limit the scope of the invention in anyway.
Characterization
Rosuvastatin intermediate of the present invention (Compound - 2) is characterized by X- Ray powder Diffraction (XRD), DSC analysis, and FTIR spectroscopy.
XRD: XRD Diffractograms were collected on Bruker AXS D-8 advance X- Ray powder diffract meter, Scintillation detector. Scanning Parameters : ScanType - Locked Coupled, Scan Mode -Continuous, Range (2 theta) - 3.0°- 60.0°, Rate - 3.6 min
FTIR Spectroscopy: FTIR Spectrum was recorded on Perkin-Elmer spectrum- 1 spectrometer, Diffuse Reflectance Technique. The sample was finely ground with Potassium Bromide, and the spectrum was recorded using Potassium Bromide background in a Diffused reflectance accessory.
Thermal analysis:
Differential Scaning Calorimetry was performed on Perkin Elmer Diamond. The Crucible was Crimped and punched prior to analysis. Experimental conditions: sample Weight: 2.0 - 3.0 mg, Heating Rate: 10°C/min.
Examples
Example 1 : Preparation of Compound- 2 using 1.0% HC1 /Methanol
A mixture of 1.0% HC1 (8.0ml), Compound - l(3.0g) and methanol (20ml) was stirred at ambient temperature for about 40—50 hrs. The separated solid was filtered ,washed with water and dried under vacuum for 10 hrs yielding compound - 2 (2.2g) as a pale yellow crystalline solid .
Example 2: Preparation of Compound- 2 using 2.0% HC1 /Methanol
A mixture of 2.0% HC1 (8.0ml), Compound - l(3.0g) and methanol (20ml) was stirred at ambient temperature for about 20 - 25 hrs. The separated solid was filtered, washed with water and dried under vacuum for 10 hrs yielding compound - 2 (2.7g) as a pale yellow crystalline solid.
Example 3: Preparation of Compound- 2 using 3.0% HC1 /Methanol A mixture of 3.0%HC1 (8.0ml), Compound -l(3.0g) and methanol (20ml) was stirred at ambient temperature for about 15 - 20 hrs. The separated solid was filtered, washed with water and dried under vacuum for 10 hrs yielding compound- 2 ( 1.8g) as a pale yellow crystalline solid .
Example 4: Preparation of Compound- 2 using 5% aq HF / Methanol
A mixture of 5.0% HF (80ml), Compound-l(14.0g) and methanol (100ml) was stirred at ambient temperature for about 40 - 50 hrs. The separated solid was filtered, washed with water and dried under vacuum for 10 hrs yielding compound - 2 ( 13.0g) as a pale yellow crystalline solid.
Example 5: Preparation of Compound- 2 using 10% aq HF / Methanol
A mixture of 10.0% HF(40ml ), Compound - l( 14.0g) and methanol ( 100ml ) was stirred at ambient temperature for about 25-30 hrs.The separated solid was filtered .washed with water and dried under vacuum for 10 hrs yielding compound- 2 ( 1 1.5g ) as a pale yellow crystalline solid .
Example 6: Preparation of Compound- 2 using 15% aq HF / Methanol
A mixture of 15.0% HF(36ml ), Compound -1 ( 14. Og) and methanol ( 100ml) was stirred at ambient temperature for about 25-30 hrs.The separated solid was filtered ,washed with water and dried under vacuum for 10 hrs yielding compound - 2 ( 14.0g) as a pale yellow crystalline solid.
Example 7: Preparation of Compound- 2 using 20% aq HF / Methanol
A mixture of 20.0% HF(20ml), Compound l(14.0g) and methanol (100ml) was stirred at ambient temperature for about 25-30 hrs.The separated solid was filtered .washed with water and dried under vacuum for 10 hrs yielding compound 2 ( 14.2g) as a pale yellow crystalline solid .

Claims

WE CLAIM
1. A crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate which provides at least one of:
(i) FTIR spectra of crystalline form of Compound-2 with peaks at 3515, 2969, 1747, 1662, 1604, 1541, 1508, 1443, 1379, 1326, 1269, 1229, 1157, 960, 903, 851, 808, 778, 565, 523, 490 cm"1,
(ii) DSC thermogram of crystalline form with endothermic peak at 105.70°C; and/or
(iii) an X-ray powder diffraction (XRPD) pattern with 5.917, 7.607,8.193, 8.88, 9.815, 10.11, 1 1.633, 12.202, 13.729, 14.725, 14.81, 15.193, 15.549, 16.2, 16.411, 16.976, 18.159, 19.024, 19.513, 19.74, 20.311, 20.875, 21.345, 21.943, 22.651, 23.563, 24.082, 24.726, 24.98, 25.2, 25.846, 26.388, 27.367, 27.654, 28.079, 28.698, 29.855, 31.38, 32.635, 33.051, 33.962, 34.753, 35.178, 35.555, 36.292, 36.574, ± 0.2 degrees two theta values.
2. The crystalline form as claimed in claim lis in isolated form.
3. The crystalline form as claimed in any one of claims 1 to 2 is in pure form.
4. The crystalline form as claimed in any one of claims 1 to 3 is in crystalline form.
5. A process for preparing crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl- 2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate , comprising steps of:
a. reacting 3(R)-(tert-Butyl-dimethyl-silanyloxy)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2- (methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-5-oxo-hept-6-enoic acid methyl ester with aqueous hydrogen halides of appropriate concentrations in an aliphatic alcohol as a solvent; and b. isolating crystalline form of Methyl-7-(4-(4-Fluorophenyl) - 6-Isopropyl-2-(N-methane sulfonylamino) pyrymidine-5-yl)-Hydroxy-5-Oxo-6-Heptonoate by filtration.
6. The process as claimed in claim 5, wherein the hydrogen halides are selected from HCl and HF.
7. The process as claimed in claim 5, wherein the solvent is selected from CI- C4 aliphatic alcohols.
8. The process as claimed in claim 7, wherein CI- C4 aliphatic alcohol is selected from a group comprising methanol, ethanol and isopropyl alcohol.
PCT/IN2010/000312 2010-03-29 2010-05-17 Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof WO2011121598A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN839CH2010 2010-03-29
IN00839/CHE/2010 2010-03-29

Publications (1)

Publication Number Publication Date
WO2011121598A1 true WO2011121598A1 (en) 2011-10-06

Family

ID=44711424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000312 WO2011121598A1 (en) 2010-03-29 2010-05-17 Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof

Country Status (1)

Country Link
WO (1) WO2011121598A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015030001A1 (en) * 2013-08-30 2015-03-05 日産化学工業株式会社 Method for manufacturing optically active 5-hydroxy-3-ketoesters

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
WO2008067440A2 (en) * 2006-11-29 2008-06-05 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
WO2009128091A2 (en) * 2008-02-20 2009-10-22 Matrix Laboratories Limited Crystalline form of(7-[4-(4-fluorophenyl)-6-isopropyl-2-(n- methyl-n-methylsulfonylamino)pyrimidin-5-yl]-(3r,5s)- dihydroxy-(e)-6-heptenoic acid intermediate, process for preparing the same and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
WO2008067440A2 (en) * 2006-11-29 2008-06-05 Dr. Reddy's Laboratories Ltd. Rosuvastatin dehydroabietylamine salt
WO2009128091A2 (en) * 2008-02-20 2009-10-22 Matrix Laboratories Limited Crystalline form of(7-[4-(4-fluorophenyl)-6-isopropyl-2-(n- methyl-n-methylsulfonylamino)pyrimidin-5-yl]-(3r,5s)- dihydroxy-(e)-6-heptenoic acid intermediate, process for preparing the same and use thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015030001A1 (en) * 2013-08-30 2015-03-05 日産化学工業株式会社 Method for manufacturing optically active 5-hydroxy-3-ketoesters
CN105473542A (en) * 2013-08-30 2016-04-06 日产化学工业株式会社 Method for manufacturing optically active 5-hydroxy-3-ketoesters
JPWO2015030001A1 (en) * 2013-08-30 2017-03-02 日産化学工業株式会社 Process for producing optically active 5-hydroxy-3-ketoesters
US9701642B2 (en) 2013-08-30 2017-07-11 Nissan Chemical Industries, Ltd. Method for producing optically active 5-hydroxy-3-ketoester
CN105473542B (en) * 2013-08-30 2018-12-04 日产化学工业株式会社 The manufacturing method of optical activity 5- hydroxyl -3- ketone ester class
JP2019135249A (en) * 2013-08-30 2019-08-15 日産化学株式会社 Manufacturing method of optically active 5-hydroxy-3-ketoesters

Similar Documents

Publication Publication Date Title
CA2527314C (en) Improved production of rosuvastatin calcium salt
EP1263739B1 (en) Crystalline salts of 7-¬4-(4-fluorophenyl)-6-isopropyl-2-¬methyl(methylsulfonyl)amino pyrimidin-5-yl -(3r,5s)-3,5-dihydroxyhept-6-enoic acid
AU2005317880B2 (en) Process for preparing rosuvastatin
WO2007000121A1 (en) A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2010091877A2 (en) Process for producing ambrisentan
CA2646795A1 (en) Process for the preparation of bosentan
NO334937B1 (en) Process for the preparation of N-cyano-N-alkylalkanesulfonamides and 4-phenylpyrimidines and such compounds
EP3472169A1 (en) METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE
WO2007147374A2 (en) Process for the preparation of solifenacin
JP6714062B2 (en) Method for preparing azoxystrobin
CA2002671C (en) Process for the production of 4,5-dichloro-6-ethyl-pyrimidine
WO2011121598A1 (en) Crystalline 7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3(r)-hydroxy-5-oxo-hept-6-enoic acid methyl ester and process thereof
CN111454216A (en) Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
WO2011114338A1 (en) A process for the preparation of highly pure ambrisentan
WO2012038785A1 (en) Polymorphs of rosuvastatin acetonide calcium ((3r,5s,6e)-7-[4-(4- fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimn)in-5- yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) acetic acid calcium salt
WO2008093205A2 (en) A method for the purification of rosuvastatin intermediate
WO2012011129A2 (en) Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
US20140275535A1 (en) Acid addition salts of bosentan
EP2867214B1 (en) Preparation process of carboxylic acid derivatives and intermediates thereof
US20050107610A1 (en) Synthesis of 2-chloro-3,6-dialkyl pyrazines
JP2007153757A (en) Method for producing 1,2-diarylamino-1,2-ethylenedicarboxylic acid alkyl ester

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10848809

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10848809

Country of ref document: EP

Kind code of ref document: A1